Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
MyCo-Triacet II, Mycogen II, Tri-Statin II, Mycolog II, Mytrex
Synonyms :
Class :
Antifungal/Corticosteroid Topicals
Brand Name :
MyCo-Triacet II, Mycogen II, Tri-Statin II, Mycolog II, Mytrex
Synonyms :
Class :
Antifungal/Corticosteroid Topicals
Dosage Forms & Strengths
cream/ointment
0.1%/100,000units/g- triamcinolone/nystatin
Dosage Forms & Strengths
cream/ointment
0.1%/100,000units/g- triamcinolone/nystatin
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
may diminish the therapeutic effect when combined
may diminish the metabolism of cyclosporine
may decrease the therapeutic effect of antifungal agents
may decrease the therapeutic effect of antifungal agents
may decrease the therapeutic effect when combined with saccharomyces boulardii
may decrease the therapeutic effect of antifungal agents
may decrease the therapeutic effect when combined with progesterone
may decrease the therapeutic effect of antifungal agents
may reduce the therapeutic effect of amphotericin
may decrease the therapeutic effect of Amphotericin B
may decrease the therapeutic effect when combined with amphotericin b
It may enhance the risk of adverse effects when combined with diagnostic agents
It may enhance the risk of adverse effects when combined with diagnostic agents
It may enhance the risk of adverse effects when combined with diagnostic agents
It may enhance the risk of adverse effects when combined with diagnostic agents
It may enhance the risk of adverse effects when combined with diagnostic agents
may decrease the therapeutic effect of Antifungal Agents
Adverse drug reactions:
Frequency Not Defined
Blistering
Dryness
Itching
Peeling
Excessive hair growth
Burning
Hair loss
Inflammation around the mouth
Irritation
Inflammation of hair follicles
Prickly heat
Secondary infection
Pregnancy warnings:
Pregnancy Category: N/A
Lactation: unknown if distributed into breast milk, avoid
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: triamcinolone acetonide/nystatin
Why do we use triamcinolone acetonide/nystatin (Rx)?
triamcinolone acetonide/nystatin is a Corticosteroids. It is used to treat Cutaneous Candidiasis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
